Synergetics Usa: (NASD: SURG)

$3.16

0.03 (0.96%)

Volume 45,739

May 17 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		3.08 - 3.17
	
		52wk Low - High
		2.88 - 5.75
	
		Previous Close
		3.13
	
		Avg. Volume
		119,758
	
		Industry
		MED INSTRUMENTS
	
		Market Cap
		79.94 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.14
	
		PE (Forward)
		26.08
	
		Current Year Est.
		0.12
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
NA

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		99 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 04/12/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            26.33
                        
                            PEG Ratio
                            1.76
                        
                            Current Year Est.
                            0.12
                        
                            Current Quarter Estimate
                            0.05
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            06-10-2013
                        
                            EPS Last Year
                            0.17
                        
                            Expected Earnings Growth
                            15.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Synergetics designs,manufactures and markets medical devices for use primarily in ophthalmic surgery and neurosurgery and for other healthcare applications. Its products are designed and manufactured to support micro or minimally invasive surgical procedures.In addition to its surgical devices and equipment,it designs and manufactures disposable and non-disposable supplies and accessories for use with such devices and equipment.   
Full SURG Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
SURG Chart  by YCharts

Earnings Estimates

	Current Qtr (04/2013)	Next Qtr (07/2013)	Current Year (07/2013)	Next Year (07/2014)
Average Estimate	0.05	0.07	0.12	0.27
Number of Estimates	1	1	1	1
Low Estimate	0.05	0.07	0.12	0.27
High Estimate	0.05	0.07	0.12	NA
Year Ago EPS	0.04	0.08	0.24	0.12
EPS Growth	25.00%	-12.50%	-50.00%	125.00%

More SURG Estimates

Average Earnings Estimates for SURG

EPS Growth for SURG

Industry Analysis

Name	Symbol	Previous Close
SYNERGETICS USA	SURG	3.16
NATUS MEDICAL	BABY	14.36
CRYOLIFE INC	CRY	6.34
DELCATH SYS INC	DCTH	0.41
GLOBUS MEDICAL	GMED	15.69
HEARTWARE INTL	HTWR	99.19
MELA SCIENCES	MELA	1.07
OXYSURE SYSTEMS	OXYS	0.90
PACIFIC BIOSCI	PACB	2.42
SUNSHINE HEART	SSH	5.49

Sector:Medical>> Industry:MED INSTRUMENTS

COMPARE TICKER vs. Its Peers

Zacks Commentary

FDA Okays Synergetics' VersaVIT

Jun 28, 2012

Synergetics 3Q Reports Mixed

Jun 12, 2012

Report for SURG

Apr 12, 2013

More SURG Zacks Commentary

Financials

EPS TTM	0.17
Sales	60
Net Income	3
Price/Earnings	18.41
Price/Book	1.37
Price/Cash Flow	10.30
Price/Sales	1.32

More SURG Financials

News

Stocks Hitting 52-Week Lows - Benzinga

Mar 19, 2013

UPDATE: Benchmark Lowers PT on Synergetics After Further Disappointment in F2Q - Benzinga

Mar 14, 2013

Benzinga`s Top Downgrades - Benzinga

Mar 13, 2013

Synergetics USA - Investors Business Daily

Mar 13, 2013

UPDATE: Wunderlich Securities Downgrades Synergetics USA after Disappointing Q2`13 Results - Benzinga

Mar 13, 2013

Earnings Scheduled For March 12, 2013 - Benzinga

Mar 12, 2013

Earnings Scheduled For October 1, 2012 - Benzinga

Oct 1, 2012

Stock Downgrades: Here`s the Beef With Wendy`s (NASDAQ:WEN) - Minyanville

Oct 1, 2012

See All News Stories on SURG

Broker Recommendations

Current ABR	2.00
ABR (Last Week)	2.00
# of recs in ABR	2
Average Target Price	6.25
Industry Rank by ABR	99 out of 265
Rank in Industry	11 out of 52

More SURG Broker Recommendations

Username: Password:

Remember me [?]

Forgot Password

New Member

Synergetics Usa: (NASD: SURG)

$3.16

0.03 (0.96%)

Volume 45,739

May 17 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks #1 Rank Strong Buys

Zacks Recommendation Long-Term: 6+ Months

All Outperform Rated Stocks

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED INSTRUMENTS

Zacks Commentary

FDA Okays Synergetics' VersaVIT

Synergetics 3Q Reports Mixed

Report for SURG

Financials

News

Stocks Hitting 52-Week Lows - Benzinga

UPDATE: Benchmark Lowers PT on Synergetics After Further Disappointment in F2Q - Benzinga

Benzinga`s Top Downgrades - Benzinga

Synergetics USA - Investors Business Daily

UPDATE: Wunderlich Securities Downgrades Synergetics USA after Disappointing Q2`13 Results - Benzinga

Earnings Scheduled For March 12, 2013 - Benzinga

Earnings Scheduled For October 1, 2012 - Benzinga

Stock Downgrades: Here`s the Beef With Wendy`s (NASDAQ:WEN) - Minyanville

Broker Recommendations

Day Low - High	3.08 - 3.17
52wk Low - High	2.88 - 5.75
Previous Close	3.13
Avg. Volume	119,758
Industry	MED INSTRUMENTS
Market Cap	79.94 M
Div - Yield	0.00 - 0.00
Beta	1.14
PE (Forward)	26.08
Current Year Est.	0.12
Quarterly Earnings ESP	NA

PE (Forward)	26.33
PEG Ratio	1.76
Current Year Est.	0.12
Current Quarter Estimate	0.05
Most Accurate Estimate	NA
Earnings ESP	NA
Next Earnings Report Date	06-10-2013
EPS Last Year	0.17
Expected Earnings Growth	15.00%